According to the website of the Center for Drug Evaluation (CDE) of China’s National Medical Products Administration, Simcere Pharmaceutical Group Limited (HKG: 2096) has filed an Investigational New Drug (IND) application for SIM0688 (former research code likely SCR‑A0011), a self‑developed B7‑H3/c‑Met bispecific antibody‑drug conjugate (ADC). SIM0688 is currently the first B7‑H3/c‑Met bispecific ADC to advance into the clinical stage — and is positioned as a global first for the modality.
Regulatory Milestone
| Item | Detail |
|---|---|
| Agency | CDE / NMPA (China) |
| Filing Type | IND (clinical trial application) |
| Product | SIM0688 (former code likely SCR‑A0011) |
| Company | Simcere Pharmaceutical Group Limited (HKG: 2096) |
| Modality | B7‑H3/c‑Met bispecific antibody‑drug conjugate (ADC) |
| Distinction | First B7‑H3/c‑Met bispecific ADC to enter clinical stage |
| Filing Date | 16 Sep 2026 |
| Proposed Indication | Not disclosed |
Drug Profile & Mechanism of Action
- Modality: Bispecific ADC — an antibody‑drug conjugate engaging two distinct tumor antigens: B7‑H3 and c‑Met, both broadly expressed across multiple solid tumor types.
- Origin: Independently developed by Simcere Pharmaceutical, filed under the code SIM0688; the former research code is likely SCR‑A0011.
- Binding Profile: Preclinical studies showed that SCR‑A0011 binds B7‑H3 and c‑Met specifically and with high affinity.
- Superior Internalization: In B7‑H3/c‑Met co‑expressing cell lines, its internalization and binding capability outperformed parental monospecific antibody ADCs — a key determinant of payload delivery efficiency.
- Developability: SCR‑A0011 demonstrated very good stability and favorable developability, supporting its progression toward clinical manufacture.
- Clinical Data: As a first‑in‑modality IND filing, no human data exist yet; trial design, dosing, and target populations were not disclosed.
Preclinical Evidence – AACR 2025 Disclosure
| Finding | Result |
|---|---|
| Antigen Binding | Specific, high‑affinity binding to both B7‑H3 and c‑Met |
| Internalization (co‑expressing lines) | Superior to parental monospecific ADCs |
| Antitumor Activity (B7‑H3/c‑Met double‑positive tumors) | Significantly stronger than parental monospecific ADCs or clinical ADCs |
| Tumor Cell Lysis | Induced across multiple tumor cell types |
| In Vivo Efficacy | Significant dose‑dependent antitumor efficacy in multiple CDX models |
In 2025, Simcere disclosed preclinical data for SCR‑A0011 at the AACR (American Association for Cancer Research) Annual Meeting. The studies showed that in B7‑H3/c‑Met double‑positive tumor cells, SCR‑A0011’s antitumor activity was significantly stronger than that of parental monospecific ADCs or clinical ADCs. The candidate induced tumor cell lysis across multiple tumor cell types, including non‑small cell lung cancer (NSCLC), colorectal cancer (CRC), ovarian cancer (OC), and head and neck squamous cell carcinoma (HNSCC), and showed significant dose‑dependent antitumor efficacy in multiple CDX (cell line‑derived xenograft) models.
Market Impact & Outlook
- First‑in‑Modality Positioning: As the first B7‑H3/c‑Met bispecific ADC entering clinical development, SIM0688 stakes a claim at the frontier of bispecific ADC engineering — where dual‑antigen engagement is designed to improve tumor selectivity, internalization, and bystander‑independent potency versus monospecific counterparts.
- Broad Solid‑Tumor Potential: The preclinical activity span across NSCLC, CRC, OC, and HNSCC supports a multi‑indication development strategy; initial clinical indication selection was not disclosed.
- Simcere Oncology Franchise: The filing extends Simcere’s self‑developed oncology pipeline and its track record of advancing ADC and bispecific modalities; global licensing or partnership plans were not disclosed.
- Next Catalysts: IND acceptance and clearance by CDE, first‑in‑human dosing, and clinical proof‑of‑concept readouts — timing not disclosed.
Forward‑Looking Statements
This brief contains forward‑looking statements regarding the clinical development of SIM0688/SCR‑A0011, including its potential across solid tumor indications. IND filing does not guarantee clearance to proceed or eventual approval. Preclinical findings, including CDX model efficacy and cell lysis data, may not translate into clinical benefit. Actual results may differ materially due to scientific, clinical, regulatory, and competitive risks.-Fineline Info & Tech
